178 results
6-K
EX-99.1
QNTM
Quantum BioPharma Ltd
27 Sep 24
Quantum Biopharma Provides Corporate Update
8:09pm
. Through its wholly owned subsidiary, Lucid Psycheceuticals Inc. (“Lucid”), Quantum BioPharma is focused on the research and development of its lead … ; the Company’s focus on the research and development of Lucid-MS to prevent and reverse myelin degradation; the Company’s intention to utilize its large tax
6-K
EX-99.1
QNTM
Quantum BioPharma Ltd
16 Sep 24
Quantum BioPharma Closes Private Placement Offering
7:27am
Psycheceuticals Inc. (“Lucid”), Quantum BioPharma is focused on the research and development of its lead compound, Lucid-MS (formerly Lucid-21-302) (“Lucid-MS
6-K
EX-99.1
QNTM
Quantum BioPharma Ltd
6 Sep 24
Quantum Biopharma Receives Nasdaq Notification of Regaining Compliance with Nasdaq’s Minimum Bid Price Requirement and Completes Debt Settlements
9:22pm
of development. Through its wholly owned subsidiary, Lucid Psycheceuticals Inc. (“Lucid”), Quantum BioPharma is focused on the research and development … on the research and development of Lucid-MS to prevent and reverse myelin degradation; the Company’s intention to utilize its large tax loss to offset future tax
6-K
EX-99.1
QNTM
Quantum BioPharma Ltd
30 Aug 24
Current report (foreign)
9:46am
research & development team at Quantum BioPharma, operated by CEO John Duffy, formerly of Coca-Cola, and co-chaired by Gerry David the former CEO … . Formulated by a world-class pharmaceutical research & development team, unbuzzd™ utilizes a proprietary blend of vitamins, minerals, and herbs to help
6-K
EX-4.1
QNTM
Quantum BioPharma Ltd
26 Aug 24
Current report (foreign)
6:04pm
, and returns. Licensor may continue to conduct research and development activities in the area of alcohol intoxication, and the development of products
6-K
EX-99.1
ec7722a
26 Aug 24
Quantum Biopharma Announces Intention to Complete Debt Settlements and Provides Corporate Update
6:18am
6-K/A
EX-99.2
j23uuo6yu2
19 Aug 24
Condensed consolidated interim financial statements
5:18pm
6-K/A
EX-99.1
f4xuw9ufmx0qo3a6biu
19 Aug 24
Condensed consolidated interim financial statements
5:18pm
6-K
EX-99.1
atv00gb3pitu jje
15 Aug 24
Current report (foreign)
7:07am
6-K
EX-99.1
v0z u6ed8rmv3xhy86k
14 Aug 24
Condensed consolidated interim financial statements
6:13am
6-K
EX-99.2
tz5fbi6q
14 Aug 24
Condensed consolidated interim financial statements
6:13am
6-K
EX-99.1
2967y1svjv3 f3
12 Aug 24
FSD Pharma Announces Share Consolidation and Name Change
6:03am
6-K
EX-99.1
4shn0wd6705ylii4gc8
9 Aug 24
Current report (foreign)
7:30am
6-K
EX-99.1
0lpur
29 Jul 24
FSD Pharma Inc. Announces Results of Annual General and Special Meeting of Shareholders
9:04pm
6-K
EX-99.2
vi86id7u8q
8 Jul 24
Amended and Restated Material Change Report
3:20pm
6-K
EX-99.1
9uyvsskos2
28 Jun 24
FSD Pharma provides Corporate Update
5:01pm
6-K
EX-99.1
ewsli46fvi06wlzk
28 Jun 24
Current report (foreign)
7:49am
6-K
EX-99.1
wq105qc9gd2xjdjo
27 Jun 24
Current report (foreign)
7:34am
6-K
EX-99.1
h9eu uq2cyro9eb7novl
13 Jun 24
Current report (foreign)
7:31am
6-K
EX-99.1
xm0 2b0lg7tzk2x4oqi
4 Jun 24
FSD Pharma Receives Institutional Review Board Approval to Study the Safety and Efficacy of Unbuzzd™ in Acute Alcohol Intoxication
8:28am